43P MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy

Autor:	T.A. Leal, D. Berz, I. Rybkin, W.T. Iams, D. Bruno, C. Blakely, A. Spira, M. Patel, D.M. Waterhouse, D. Richards, A. Pham, R. Jotte, E.B. Garon, D.S. Hong, R. Shazer, X. Yan, L. Latven, K. He
Rok vydání:	2022
Předmět:	Oncology Hematology
Zdroj:	Annals of Oncology. 33:S19-S20
ISSN:	0923-7534
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::18f4e7efb25da79ac6de868f424f5d2e https://doi.org/10.1016/j.annonc.2022.01.052 Zobrazit plný text záznamu